ES2675779T3 - Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R - Google Patents
Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R Download PDFInfo
- Publication number
- ES2675779T3 ES2675779T3 ES13765844.9T ES13765844T ES2675779T3 ES 2675779 T3 ES2675779 T3 ES 2675779T3 ES 13765844 T ES13765844 T ES 13765844T ES 2675779 T3 ES2675779 T3 ES 2675779T3
- Authority
- ES
- Spain
- Prior art keywords
- treatment
- atopic dermatitis
- antagonist
- administering
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/202—Dermatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
Abstract
Una composición farmacéutica que comprende una cantidad terapéuticamente eficaz de un anticuerpo anti- receptor de interleucina-4 humana (IL-4R), o fragmento de unión al antígeno del mismo, para su uso en un método de tratamiento en un paciente de la dermatitis atópica de moderada a grave, en la que el paciente es resistente, no sensible o inadecuadamente sensible, a corticosteroides tópicos o a inhibidores tópicos de calcineurina.
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261697972P | 2012-09-07 | 2012-09-07 | |
| US201261697972P | 2012-09-07 | ||
| US201261738715P | 2012-12-18 | 2012-12-18 | |
| US201261738715P | 2012-12-18 | ||
| US201361748588P | 2013-01-03 | 2013-01-03 | |
| US201361748588P | 2013-01-03 | ||
| US201361764624P | 2013-02-14 | 2013-02-14 | |
| US201361764624P | 2013-02-14 | ||
| US201361768229P | 2013-02-22 | 2013-02-22 | |
| US201361768229P | 2013-02-22 | ||
| US201361770091P | 2013-02-27 | 2013-02-27 | |
| US201361770091P | 2013-02-27 | ||
| US201361782420P | 2013-03-14 | 2013-03-14 | |
| US201361782420P | 2013-03-14 | ||
| US201361816191P | 2013-04-26 | 2013-04-26 | |
| US201361816191P | 2013-04-26 | ||
| FR1356759 | 2013-07-10 | ||
| FR1356759 | 2013-07-10 | ||
| PCT/US2013/057898 WO2014039461A1 (en) | 2012-09-07 | 2013-09-04 | Methods for treating atopic dermatitis by administering an il-4r antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2675779T3 true ES2675779T3 (es) | 2018-07-12 |
Family
ID=50233497
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13765844.9T Active ES2675779T3 (es) | 2012-09-07 | 2013-09-04 | Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R |
| ES21167811T Active ES2981062T3 (es) | 2012-09-07 | 2013-09-04 | Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES21167811T Active ES2981062T3 (es) | 2012-09-07 | 2013-09-04 | Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US20140072583A1 (es) |
| EP (4) | EP4374919A3 (es) |
| JP (4) | JP6353838B2 (es) |
| KR (3) | KR102385501B1 (es) |
| CN (3) | CN118286417A (es) |
| AR (1) | AR092475A1 (es) |
| AU (4) | AU2013312868B2 (es) |
| BR (1) | BR112015005048A8 (es) |
| CA (1) | CA2883936C (es) |
| CY (1) | CY1121906T1 (es) |
| DK (1) | DK2892927T3 (es) |
| ES (2) | ES2675779T3 (es) |
| HK (1) | HK1209132A1 (es) |
| HR (1) | HRP20181227T1 (es) |
| HU (2) | HUE066738T2 (es) |
| IL (1) | IL237328B (es) |
| LT (1) | LT2892927T (es) |
| MX (1) | MX363193B (es) |
| NZ (3) | NZ630178A (es) |
| PL (1) | PL2892927T3 (es) |
| PT (1) | PT3889181T (es) |
| RS (1) | RS57520B1 (es) |
| RU (2) | RU2698907C2 (es) |
| SG (2) | SG11201501011WA (es) |
| SI (1) | SI2892927T1 (es) |
| SM (1) | SMT201800396T1 (es) |
| TR (1) | TR201808181T4 (es) |
| TW (4) | TWI699212B (es) |
| UY (1) | UY35013A (es) |
| WO (1) | WO2014039461A1 (es) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| PL3354280T3 (pl) | 2010-10-06 | 2021-02-08 | Regeneron Pharmaceuticals, Inc. | Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny 4 (IL-4R) |
| BR112015003590A8 (pt) | 2012-08-21 | 2017-10-31 | Sanofi Sa | Métodos para tratamento ou prevenção da asma por administração de um antagonista de il-4r |
| EP4374919A3 (en) | 2012-09-07 | 2024-08-21 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| TWI697334B (zh) * | 2013-06-04 | 2020-07-01 | 美商再生元醫藥公司 | 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
| AU2014284235B2 (en) | 2013-06-21 | 2019-11-21 | Regeneron Pharmaceuticals, Inc. | Methods for treating nasal polyposis by administering an IL-4R antagonist |
| TWI682781B (zh) | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| IL315136A (en) | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| RU2704999C2 (ru) | 2014-02-28 | 2019-11-01 | Ридженерон Фармасьютикалз, Инк. | Способ лечения кожной инфекции путем введения антагониста il-4r |
| US10584344B2 (en) * | 2014-06-17 | 2020-03-10 | Crown Laboratories, Inc. | Genetically modified bacteria and methods for genetic modification of bacteria |
| TWI745962B (zh) * | 2014-06-27 | 2021-11-11 | 法商賽諾菲公司 | 測定投予至人類個體之包括雙-v-區類抗體蛋白或其片段的劑量是否在人類個體中與il-4或il-13特異性結合之方法 |
| WO2016077675A1 (en) | 2014-11-14 | 2016-05-19 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
| CA3232651A1 (en) | 2015-04-02 | 2016-10-06 | Intervet International B.V. | Antibodies to canine interleukin-4 receptor alpha |
| EP3284480A4 (en) | 2015-04-14 | 2018-12-05 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient |
| ES2983475T3 (es) * | 2016-02-19 | 2024-10-23 | Regeneron Pharma | Métodos para mejorar la eficacia de una vacuna mediante la administración de un antagonista de IL-4R |
| CN113372446A (zh) | 2016-06-08 | 2021-09-10 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
| EP3506931B1 (en) * | 2016-09-01 | 2024-07-31 | Regeneron Pharmaceuticals, Inc. | Methods for preventing or treating allergy by administering an il-4r antagonist |
| EP3515465B1 (en) | 2016-09-22 | 2024-02-07 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor |
| HRP20231015T1 (hr) | 2016-09-23 | 2023-12-08 | F. Hoffmann-La Roche Ag | Upotreba antagonista il-13 u liječenju atopičnog dermatitisa |
| TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| US11053309B2 (en) | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
| PT3515465T (pt) | 2017-08-18 | 2024-03-04 | Regeneron Pharma | Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r |
| PL3703818T3 (pl) | 2017-10-30 | 2024-03-25 | Sanofi Biotechnology | Antagonista IL-4R do zastosowania w sposobie leczenia lub zapobiegania astmie |
| AU2018360999A1 (en) * | 2017-10-31 | 2020-05-14 | Oneness Biotech Co. Ltd. | Treating IgE-mediated allergic diseases |
| AU2018360059B2 (en) | 2017-11-03 | 2023-07-13 | Aclaris Therapeutics, Inc. | Substituted pyrrolopyrimidine JAK inhibitors and methods of making and using the same |
| CN111656382A (zh) * | 2018-01-31 | 2020-09-11 | 美道寻济株式会社 | 广告提示方法及广告提示系统 |
| MA52624A (fr) * | 2018-05-13 | 2021-03-24 | Regeneron Pharma | Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r |
| WO2020033955A1 (en) | 2018-08-10 | 2020-02-13 | Aclaris Therapeutics, Inc. | Pyrrolopyrimidine itk inhibitors |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| US11497718B2 (en) | 2018-11-13 | 2022-11-15 | Dermavant Sciences GmbH | Use of tapinarof for the treatment of atopic dermatitis |
| CN111514292B (zh) * | 2018-12-25 | 2023-06-20 | 江苏荃信生物医药股份有限公司 | 抗人白介素4受体α单克隆抗体的制药用途 |
| JP2022526738A (ja) | 2019-03-21 | 2022-05-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | アレルギーを治療するためのｉｌ－４／ｉｌ－１３経路阻害剤と形質細胞除去の組み合わせ |
| TWI861073B (zh) * | 2019-03-21 | 2024-11-11 | 美商再生元醫藥公司 | 含有抗il-33抗體之穩定調配物 |
| CN111592597B (zh) * | 2019-05-29 | 2022-04-26 | 山东博安生物技术股份有限公司 | 白介素4受体(il-4r)结合蛋白及其用途 |
| WO2021026203A1 (en) | 2019-08-05 | 2021-02-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist |
| MX2022001247A (es) | 2019-08-05 | 2022-04-25 | Regeneron Pharma | Metodos para tratar dermatitis atopica mediante la administracion de un antagonista il-4r. |
| US11748800B1 (en) * | 2019-09-11 | 2023-09-05 | Life Spectacular, Inc. | Generating skin care recommendations for a user based on skin product attributes and user location and demographic data |
| CN111825766B (zh) * | 2019-10-31 | 2021-05-11 | 上海洛启生物医药技术有限公司 | 抗il-4r单域抗体及其应用 |
| IL293487A (en) | 2019-12-09 | 2022-08-01 | Sanofi Biotechnology | Methods for treating digitally-identified il-4/il-13 related disorders |
| US20230102151A1 (en) | 2020-03-27 | 2023-03-30 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| CN116761582A (zh) | 2020-06-23 | 2023-09-15 | 皇冠实验室有限公司 | 益生菌皮肤制剂 |
| EP4019547A1 (en) | 2020-12-23 | 2022-06-29 | Numab Therapeutics AG | Multispecific antibodies having specificity for il-4r and il-31 |
| CA3205006A1 (en) | 2020-12-23 | 2022-06-30 | Numab Therapeutics AG | Antibody variable domains that bind il-4r |
| EP4019090A1 (en) | 2020-12-23 | 2022-06-29 | Numab Therapeutics AG | Antibody variable domains that bind il-4r |
| US11581084B2 (en) * | 2020-12-29 | 2023-02-14 | Kpn Innovations, Llc. | Systems and methods for generating an alimentary plan for managing skin disorders |
| TW202302104A (zh) * | 2021-02-18 | 2023-01-16 | 美商阿克拉里斯醫療股份有限公司 | Jak 1/3抑制劑的局部配方及其用於治療異位性皮膚炎和其他皮膚狀況之用法 |
| JP2024532263A (ja) | 2021-08-23 | 2024-09-05 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｉｌ－４ｒアンタゴニストを投与することによってアトピー性皮膚炎を治療する方法 |
| WO2023191665A1 (en) * | 2022-03-31 | 2023-10-05 | Milaboratory, Limited Liability Company | ANTIBODIES TO HUMAN IL-4Rα HAVING REDUCED IMMUNOGENICITY AND APPLICATION THEREOF |
| WO2024076731A1 (en) * | 2022-10-06 | 2024-04-11 | Regranion, Llc | Methods and compositions for treating hidradenitis suppurativa |
| WO2024097714A1 (en) | 2022-11-01 | 2024-05-10 | Regeneron Pharmaceuticals, Inc. | Methods for treating hand and foot dermatitis by administering an il-4r antagonist |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3315427B2 (ja) * | 1992-03-05 | 2002-08-19 | 大日本除蟲菊株式会社 | 皮膚炎治療剤 |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| EP2292665B1 (en) | 2000-05-26 | 2015-07-08 | Immunex Corporation | Use of interleukin-4 antibodies and compositions thereof |
| KR100572408B1 (ko) * | 2000-07-26 | 2006-04-19 | 가부시키가이샤 호오도 | 진양성 조성물 및 창상치유촉진 조성물 |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JP5234445B2 (ja) * | 2004-10-05 | 2013-07-10 | 源一郎 杣 | 薬剤 |
| BRPI0611069A2 (pt) | 2005-05-06 | 2010-11-09 | Zymogenetics Inc | anticorpo monoclonal, anticorpo humanizado, fragmento de anticorpo, uso de um antagonista, e, hibridoma |
| EP2374818B1 (en) | 2006-06-02 | 2012-12-19 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human IL-6 receptor |
| US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| PL3354280T3 (pl) | 2010-10-06 | 2021-02-08 | Regeneron Pharmaceuticals, Inc. | Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny 4 (IL-4R) |
| RU2453303C1 (ru) * | 2010-12-23 | 2012-06-20 | Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") | Фармацевтическая композиция для лечения атопического дерматита |
| EP4374919A3 (en) * | 2012-09-07 | 2024-08-21 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| WO2022076289A1 (en) | 2020-10-05 | 2022-04-14 | Sanofi Biotechnology | Methods for treating asthma in pediatric subjects by administering an il-4r antagonist |
-
2013
- 2013-09-04 EP EP24163612.5A patent/EP4374919A3/en active Pending
- 2013-09-04 HU HUE21167811A patent/HUE066738T2/hu unknown
- 2013-09-04 SG SG11201501011WA patent/SG11201501011WA/en unknown
- 2013-09-04 MX MX2015002873A patent/MX363193B/es unknown
- 2013-09-04 JP JP2015531149A patent/JP6353838B2/ja active Active
- 2013-09-04 RU RU2018131237A patent/RU2698907C2/ru active
- 2013-09-04 BR BR112015005048A patent/BR112015005048A8/pt not_active Application Discontinuation
- 2013-09-04 NZ NZ630178A patent/NZ630178A/en unknown
- 2013-09-04 DK DK13765844.9T patent/DK2892927T3/en active
- 2013-09-04 PL PL13765844T patent/PL2892927T3/pl unknown
- 2013-09-04 KR KR1020217023487A patent/KR102385501B1/ko active Active
- 2013-09-04 NZ NZ748451A patent/NZ748451A/en unknown
- 2013-09-04 CN CN202410387527.8A patent/CN118286417A/zh active Pending
- 2013-09-04 SI SI201331084T patent/SI2892927T1/sl unknown
- 2013-09-04 SG SG10201701798TA patent/SG10201701798TA/en unknown
- 2013-09-04 CN CN201380046623.6A patent/CN104995212A/zh active Pending
- 2013-09-04 RS RS20180802A patent/RS57520B1/sr unknown
- 2013-09-04 LT LTEP13765844.9T patent/LT2892927T/lt unknown
- 2013-09-04 HU HUE13765844A patent/HUE039387T2/hu unknown
- 2013-09-04 WO PCT/US2013/057898 patent/WO2014039461A1/en active Application Filing
- 2013-09-04 KR KR1020157008872A patent/KR102122708B1/ko active Active
- 2013-09-04 CN CN202410387417.1A patent/CN118286430A/zh active Pending
- 2013-09-04 EP EP13765844.9A patent/EP2892927B1/en not_active Revoked
- 2013-09-04 US US14/017,333 patent/US20140072583A1/en not_active Abandoned
- 2013-09-04 EP EP18161065.0A patent/EP3354663A1/en not_active Withdrawn
- 2013-09-04 NZ NZ731864A patent/NZ731864A/en unknown
- 2013-09-04 AU AU2013312868A patent/AU2013312868B2/en active Active
- 2013-09-04 CA CA2883936A patent/CA2883936C/en active Active
- 2013-09-04 TR TR2018/08181T patent/TR201808181T4/tr unknown
- 2013-09-04 SM SM20180396T patent/SMT201800396T1/it unknown
- 2013-09-04 ES ES13765844.9T patent/ES2675779T3/es active Active
- 2013-09-04 ES ES21167811T patent/ES2981062T3/es active Active
- 2013-09-04 KR KR1020227011429A patent/KR102576903B1/ko active Active
- 2013-09-04 RU RU2015108073A patent/RU2666630C2/ru active
- 2013-09-04 EP EP21167811.5A patent/EP3889181B1/en active Active
- 2013-09-04 PT PT211678115T patent/PT3889181T/pt unknown
- 2013-09-05 TW TW107106951A patent/TWI699212B/zh active
- 2013-09-05 TW TW111134046A patent/TWI814575B/zh active
- 2013-09-05 TW TW102131927A patent/TWI690328B/zh active
- 2013-09-05 TW TW112129255A patent/TWI852712B/zh active
- 2013-09-06 AR ARP130103184A patent/AR092475A1/es unknown
- 2013-09-06 UY UY0001035013A patent/UY35013A/es unknown
-
2015
- 2015-02-19 IL IL237328A patent/IL237328B/en unknown
- 2015-09-29 HK HK15109558.8A patent/HK1209132A1/xx not_active IP Right Cessation
-
2017
- 2017-05-31 US US15/610,267 patent/US20170333557A1/en not_active Abandoned
-
2018
- 2018-06-08 JP JP2018109925A patent/JP6637113B2/ja active Active
- 2018-06-18 AU AU2018204346A patent/AU2018204346B2/en active Active
- 2018-07-27 CY CY20181100782T patent/CY1121906T1/el unknown
- 2018-07-31 HR HRP20181227TT patent/HRP20181227T1/hr unknown
-
2019
- 2019-12-10 AU AU2019279946A patent/AU2019279946B2/en active Active
-
2021
- 2021-09-23 AU AU2021236538A patent/AU2021236538B2/en active Active
-
2022
- 2022-09-23 US US17/951,987 patent/US20230058395A1/en active Pending
-
2023
- 2023-03-29 JP JP2023052545A patent/JP2023082091A/ja active Pending
-
2024
- 2024-11-13 JP JP2024197857A patent/JP2025024077A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2675779T3 (es) | Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R | |
| AR092177A1 (es) | Metodos para tratar o prevenir asma administrando un antagonista de il-4r | |
| CY1122466T1 (el) | Σκευασμα αντισωματος αντι il-17ra και θεραπευτικα σχηματα για την αγωγη της ψωριασης | |
| CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
| CY1121150T1 (el) | Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας | |
| MX2016004580A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
| BR112012028136A2 (pt) | terapia de combinaçao | |
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| CL2015001891A1 (es) | Formas de dosis de liberación controlada encerradas resistentes a manipulaciones indebidas; uso para tratar el dolor; y metodo de preparacion. (divisional de la solicitud n°2754-2014). | |
| MX2016000271A (es) | Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r. | |
| EA201491011A1 (ru) | Способы лечения с помощью ингибитора гамма-интерферона | |
| CO7200273A2 (es) | Combinaciones farmaceúticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa | |
| EA201591591A1 (ru) | Соединения карбазола, применяемые в качестве ингибиторов бромодомена | |
| BR112013021863A2 (pt) | anticorpos anti-receptor il-6 e métodos de uso | |
| EA201691032A1 (ru) | Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ | |
| EA201400002A1 (ru) | Способы лечения заболеваний сетчатки | |
| TR201905101T4 (tr) | Doku faktörü yolak inhibitörüne (TFPI) karşı monoklonal antikorlar. | |
| BR112012027197A2 (pt) | combinação ou composição farmacêutica, seu uso, kit, e compostos para tratamento de doenças oncológicas e fibróticas | |
| ECSP16008797A (es) | Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos | |
| UY34116A (es) | El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico | |
| BR112016002401A2 (pt) | métodos para reduzir as taxas de exacerbação de asma usando benralizumab | |
| AR124497A2 (es) | Métodos para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos métodos, y composición farmacéutica | |
| BR112013023970A2 (pt) | composição farmacêutica, dispositivo, inibidor de hdac, kit, método de pré-tratamento de um ser humano que sofre de câncer e método de avaliação do efeito de uma substância sobre a sensibilidade a chop de linhagens celulares | |
| MX2014002395A (es) | Inhibidores de rock suaves, novedosos. | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 |